P-266 Pre-clinical characterization of SAR442257, a CD38xCD28xCD3 trispecific T-cell engager in relapsed/refractory multiple myeloma
Anna Luise Grab(German Cancer Research Center), Marc S. Raab(Unknown), Debarati Shome, Niels Weinhold(German Cancer Research Center), Kamlesh Bisht, Irene Sarka(Sarah Cannon), Peter Kim(Sanofi (United States)), Lukas John(University of Hohenheim), Hongfang Wang(Memorial Sloan Kettering Cancer Center), Halgi Vandevelde(Sanofi (Mexico))
Cited by 0
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
|Blood|2018|492
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
|Leukemia|2018|452
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
|Nature Communications|2017|418
NOTCH1–RBPJ complexes drive target gene expression through dynamic interactions with superenhancers
|Proceedings of the National Academy of Sciences|2013|266